MCL Literature Feed

In a large real-world analysis, R-CHOP/R-DHAP trended toward better OS in transplant-eligible patients, while rituximab maintenance, not initial chemo, drove survival in transplant-ineligible patients.

A deep learning model fusing PET/CT and EHR data creates a new signature that better predicts survival in frontline MCL, potentially improving risk-adapted therapy selection.

This review outlines the evolving MCL treatment paradigm, detailing the integration of BTKi, CAR-T, and bispecific antibodies in both frontline and relapsed/refractory settings to improve patient outcomes.

This case report details severe, reversible myocarditis from bortezomib, a rare but critical cardiotoxicity for clinicians to recognize in MCL patients receiving proteasome inhibitor-based therapy.

This first real-world analysis of ASCT for MCL in Argentina confirms its efficacy but identifies blastoid variant, age ≥55, and high comorbidities as independent predictors of poor survival.

This large, real-world study demonstrates that any disease progression, even occurring more than 6 years after initial therapy, significantly worsens overall survival in mantle cell lymphoma.

Frontline zanubrutinib-rituximab induction achieved an 88% complete response rate, enabling a shortened R-DHAOx consolidation, offering a highly effective, chemotherapy-de-escalation strategy for newly diagnosed MCL.

High serum sTNFR2 at diagnosis is a strong prognostic biomarker for inferior overall survival in MCL, implicating the tumor microenvironment and suggesting a new therapeutic target.

An expert panel opinion advocates for personalized MCL therapy, positioning BTKi as a frontline standard for transplant-ineligible patients and a potential alternative to consolidation transplant for others.

Adding ibrutinib to intensive frontline immunochemotherapy for newly diagnosed, fit MCL patients aims to deepen responses and improve outcomes, often as induction before transplant consolidation.

Zanubrutinib plus age-adapted bendamustine-rituximab induction followed by zanubrutinib maintenance demonstrates high efficacy (75% 2-year PFS) and deep responses (94% uMRD) in elderly, frontline MCL patients.

This case report details pleomorphic MCL presenting as life-threatening hemophagocytic lymphohistiocytosis (HLH), emphasizing the need for high clinical suspicion of this rare, sepsis-mimicking oncologic emergency.

This case of MCL presenting as diffuse gastrointestinal polyposis mimicking hereditary syndromes underscores the need for histopathology to avoid misdiagnosis and ensure prompt immunochemotherapy for this rare presentation.

Undetectable MRD after induction chemotherapy identifies mantle cell lymphoma patients who may safely omit consolidative autologous stem cell transplant, enabling a personalized, de-escalation treatment strategy.

This phase 2 study of frontline acalabrutinib, lenalidomide, and anti-CD20 demonstrates high molecular response rates (67-90%) and 76% 4-year PFS, supporting a time-limited, MRD-driven, chemotherapy-free treatment strategy.

This large retrospective study shows rituximab maintenance after first-line bendamustine-rituximab significantly improves both event-free and overall survival, supporting its use as a standard of care.

Population-level data confirms rituximab maintenance improves overall survival after R-CHOP induction, with a notable benefit for patients achieving only a partial response.

This real-world study shows bendamustine-rituximab is the most common frontline therapy and BTK inhibitors for second-line, but median overall survival plummets in later lines, highlighting significant unmet need.

The combination of acalabrutinib with bendamustine-rituximab is evaluated as a frontline therapy for elderly MCL patients, aiming to improve outcomes over standard chemoimmunotherapy.

This Chinese real-world study confirms autologous transplant consolidation improves survival in young, fit, lower-risk MCL, with added benefit from post-transplant maintenance using novel agents.

This review outlines the evolution of BTK inhibitors, highlighting how non-covalent agents like pirtobrutinib overcome C481-mediated resistance, extending the therapeutic sequence for relapsed/refractory MCL.

This case report details a rare MCL-induced paraneoplastic 'full-house' nephropathy mimicking lupus nephritis, which resolved with lymphoma-directed therapy, expanding the spectrum of known renal complications.

In the phase 3 TRIANGLE trial for young, fit MCL, adding ibrutinib to induction immunochemotherapy improves failure-free survival, with noninvasive genotyping confirming its efficacy and treatment dynamics.

A new genomic model integrating mutations (e.g., TP53) and copy number variations improves risk stratification for elderly, newly diagnosed MCL patients treated with chemoimmunotherapy.

This review summarizes the shift towards frontline BTK inhibitor-based regimens, including chemotherapy-free options and combinations for high-risk MCL, potentially replacing autologous stem cell transplant consolidation.

The phase 3 TRIANGLE trial shows adding ibrutinib to frontline chemoimmunotherapy and autologous transplant improves failure-free survival, establishing a new standard of care for young, fit MCL patients.

In the MCL0208 trial for young patients, IGHV mutation status and stereotyped receptors predicted outcomes after intensive chemoimmunotherapy and transplant, offering a new biomarker for frontline risk stratification.

A rare case of MCL presenting as a parotid gland neoplasm highlights the importance of considering systemic lymphoma in atypical head/neck masses to ensure timely diagnosis and therapy.

This real-world Colombian cohort confirms MIPI score as a key prognostic factor in MCL, where age-stratified frontline chemotherapy resulted in comparable responses despite different treatment intensities.

This review summarizes the MCL treatment evolution from chemoimmunotherapy and transplant to targeted agents (BTKi) and immunotherapies (CAR-T, bispecifics), emphasizing a future of personalized, genomics-guided care.